循環器ジャーナル65巻1号

2017年01月発行

特集 Clinical Scenarioによる急性心不全治療 Ⅴ．Clinical Scenario 3：低心拍出を伴う急性心不全

急性心不全治療薬としての強心薬のエビデンス

著者： 志賀剛¹

所属機関： ¹東京女子医科大学循環器内科

ページ範囲：P.85 - P.91

Point
・強心薬は心筋の細胞内カルシウム濃度を上昇し，心筋収縮を強めることで心拍出量を増やす．
・急性心不全に対する強心薬静注は，血行動態や心不全症状を改善するが，死亡リスクを上げる．
・強心薬静注の適応は低心拍出量に伴う臓器・組織低灌流の症候がある心不全で，短期間の使用にとどめる．

参考文献

1) Packer M, Carver JR, Rodeheffer RJ, et al:for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468-1475, 1991

2) Gheorghiade M, St Clair J, St Clair C, et al:Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 9:849-857, 1987

3) Gheorghiade M, Hall V, Lakier JB, et al:Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 13:134-142, 1989

4) Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure. Am J Cardiol 69:34G-47G, 1992

5) Unverferth DV, Magorien RD, Lewis RP, et al:Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 100:622-630, 1980

6) Unverferth DV, Magorien RD, Altschuld R, et al:The hemodynamic and metabolic advantages gained by three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 106:29-33, 1983

7) Liang CS, Sherman LG, Doherty JU, et al:Sustained improvement in cardiac function in patients with congestive heart failure after short-term infusions of dobutamine. Circulation 69:113-119, 1984

8) O'Connor CM, Gattis WA, Uretsky BF, et al:Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure:insights from the Flolan International Randomized Survival Trial（FIRST). Am Heart J 138:78-86, 1999

9) Silver MA, Horton DP, Ghali JK, et al:Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39:798-803, 2002

10) Burger AJ, Horton DP, LeJemtel T, et al;for the Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy:Effect of nesiritide（B-type natriuretic peptide）and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure:the PRECEDENT [Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy] study. Am Heart J 144:1102-1108, 2002

11) Oliva F, Latini R, Politi A, et al:Intermittent 6-month low-dose dobutamine infusion in severe heart failure:DICE multicenter trial. Am Heart J 138:247-253, 1999

12) Shin DD, Brandimarte F, De Luca L, et al:Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99(2A):4A-23A, 2007

13) Maskin CS, Ocken S, Chadwick B, et al:Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation 72:846-852, 1985

14) Shipley JB, Tolman D, Hastillo A, et al:Milrinone:basic and clinical pharmacology and acute and chronic management. Am J Med Sci 311:286-291, 1996

15) Cuffe MS, Califf RM, Adams KF Jr, et al;Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure（OPTIMECHF）Investigators:Short-term intravenous milrinone for acute exacerbation of chronic heart failure:a randomized controlled trial. JAMA 287:1541-1547, 2002

16) Felker GM, Benza RL, Chandler AB, et al;OPTIME-CHF Investigators:Heart failure etiology and response to milrinone in decompensated heart failure:results from the OPTIME-CHF study. J Am Coll Cardiol 41:997-1003, 2003

17) Kivikko M, Lehtonen L, Colucci WS:Sustained hemodynamic effects of intravenous levosimendan. Circulation 107:81-86, 2003

18) McBride BF, White CM:Levosimendan:implications for clinicians. J Clin Pharmacol 43:1071-1081, 2003

19) Moiseyev VS, Poder P, Andrejevs N, et al;RUSSLAN　Study Investigators:Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction:a randomized, placebo-controlled, double-blind study（RUSSLAN). Eur Heart J 23:1422-1432, 2002

20) Follath F, Cleland JG, Just H, et al:Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure（the LIDO study):a randomized double-blind trial. Lancet 360:196-202, 2002

21) Zairis MN, Apostolatos C, Anastassiadis F, et al:Comparison of the effect of levosimendan, or dobutamine or placebo in chronic low output decompensated heart failure:Calcium Sensitizer or Inotrope or None in Low Output Heart Failure（CASINO）study. In:Program and abstracts of the European Society of Cardiology, heart failure Update 2004. Wroclaw, Poland, pp12-15, 2004

22) Packer M, Colucci W, Fisher L, et al;REVIVE Heart Failure Study Group:Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 1:103-111, 2013

23) Mebazaa A, Nieminen MS, Packer M, et al;SURVIVE Investigators:Levosimendan vs dobutamine for patients with acute decompensated heart failure:the SURVIVE Randomized Trial. JAMA 297:1883-1891, 2007

24) Gheorghiade M, Abraham WT, Albert NM, et al;OPTIMIZE-HF Investigators and Coordinators:Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296:2217-2226, 2006

25) Nieminen MS, Brutsaert D, Dickstein K, et al;EuroHeart Survey Investigators, Heart Failure Association:European Society of Cardiology. EuroHeart Failure Survey Ⅱ（EHFS Ⅱ):a survey on hospitalized acute heart failure patients:description of population. Eur Heart J 27:2725-2736, 2006

26) Yancy CW, Lopatin M, Stevenson LW, et al;ADHERE Scientific Advisory Committee and Investigators:Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function:a report from the Acute Decompensated Heart Failure National Registry（ADHERE）Database. J Am Coll Cardiol 47:76-84, 2006

27) Adams KF Jr, Fonarow GC, Emerman CL, et al;ADHERE Scientific Advisory Committee and Investigators:Characteristics and outcomes of patients hospitalized for heart failure in the United States:rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry（ADHERE). Am Heart J 149:209-216, 2005

28) Abraham WT, Adams KF, Fonarow GC, et al;ADHERE Scientific Advisory Committee and Investigators, ADHERE Study Group:In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications:an analysis from the Acute Decompensated Heart Failure National Registry（ADHERE). J Am Coll Cardiol 46:57-64, 2005

29) Elkayam U, Tasissa G, Binanay C, et al:Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153:98-104, 2007

30) Ponikowski P, Voors AA, Anker SD, et al;Authors/Task Force Members:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology（ESC）Developed with the special contribution of the Heart Failure Association（HFA）of the ESC. Eur Heart J 37:2129-2200, 2016